Doctor of Osteopathy Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Norman Frey

Geriatric Medicine Pittsburgh, PA Doctor of Osteopathy

NPI 1487652012 CMS profile 860766

3000 Brownsville Rd Ste B, Pittsburgh, PA 15227

Open in the dashboard

General payments

$70

5 records reported · program years 2019–2022

Research payments

$150

Paid to them · 1 record reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Norman Frey of Pittsburgh, PA is reported in the CMS Open Payments database as having received $70 across 5 general payments and $150 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $22 1
2020 Research $150 1
2019 General $48 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Norman Frey
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Norman Frey were reported at $0. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year Norman Frey Geriatric Medicine median Middle half National median
2019 $48 $96 $28–$339 $163
2020 $0 $99 $28–$262 $114
2021 $0 $94 $27–$318 $132
2022 $22 $103 $34–$338 $149
2023 $0 $109 $39–$320 $160
2024 $0 $125 $36–$371 $164
2025 $0 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Pfizer Inc. $22 2 payments
  2. CSL Behring $22 1 payment
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $15 1 payment
  4. AstraZeneca Pharmaceuticals LP $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $55 4 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2022
  1. ELIQUIS $22 2 payments
  2. CHANTIX $22 2 payments
  3. Kcentra $22 1 payment
  4. SPIRIVA RESPIMAT $15 1 payment
  5. FARXIGA $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2022
  1. Indivior Inc. $150 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 230 drugs

Part D claims

20,776

Median for Family Practice: 1,826

Drug cost

$1,576,193

Median for Family Practice: $120,094

Branded share of claims

22.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 428 $292,668
Jardiance Empagliflozin Brand 241 $210,559
Ozempic Semaglutide Brand 109 $113,307
Mounjaro Tirzepatide Brand 77 $89,139
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 100 $81,746
Xarelto Rivaroxaban Brand 91 $63,905
Xifaxan Rifaximin Brand 12 $37,298
Myrbetriq Mirabegron Brand 81 $37,137
Entresto Sacubitril/Valsartan Brand 51 $35,374
Farxiga Dapagliflozin Propanediol Brand 59 $32,854

The 10 drugs with the highest cost, of 230 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$61,699

Of which drugs: $4,412

Medicare patients

170

Average age 79

Services billed

1,141

99 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Alzheimer's or dementia 32%
Diabetes 30%
Heart failure 29%
Ischemic heart disease 29%
Atrial fibrillation 28%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 31 31 $2,127
Influenza vaccine, trivalent derived from cell cultures 90661 Office 13 13 $469

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record